The FDA apparently deems an uncontrolled study acceptable – five months after saying no.
ApexOnco Front Page
Recent articles
Could RO7851624, newly into clinical trials, be RG6735?
Evopoint reveals intriguing but opaque first-in-human data for XNW27011.
Bristol buys into the frenzy, and VEGF bispecific value inflation continues.
Enhertu plus Perjeta shows a convincing progression-free survival benefit over a Perjeta triplet.
But camizestrant’s use could depend on uptake of monitoring – for now.
The company highlights the safety of its KLK2-targeting T-cell engager pasritamig.
As patritumab-dxd's problems mount, Astra's decision to say no to this project looks smart.